March 3, 2026Open Access

In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States

Key Points

Ceftobiprole inhibited 99.8% of staphylococcus aureus isolates, demonstrating significant antimicrobial activity.
Among methicillin-resistant strains, susceptibility was still high at 99.5%, highlighting its effectiveness.
Analysis involved 8,123 gram-positive bacterial isolates from skin infection cases across 33 hospitals.
Findings suggest that ceftobiprole could be a key option for treating skin and skin structure infections.

Abstract

We evaluated the susceptibility of 8,123 Gram-positive bacteria from patients with skin and skin structure infections at 33 US hospitals. Ceftobiprole inhibited 99.8% of Staphylococcus aureus, including 99.5% of methicillin-resistant isolates, at ≤2 mg/L. Ceftobiprole was highly active against β-hemolytic streptococci, coagulase-negative staphylococci, viridans group streptococci, and Enterococcus faecalis isolates.

In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States

Key Points

Abstract

Cite This Study